Similar articles

• Antibody response to A/Asian component of polyvalent influenza virus vaccine.

  DUXBURY AE, WARBURTON MF, GREVILLE RW. DUXBURY AE, et al. Med J Aust. 1959 Jun 13;1(24):790-3. doi: 10.5694/j.1326-5377.1959.tb88876.x. Med J Aust. 1959. PMID: 13666176 No abstract available.
• Antibody response in man to two doses of polyvalent influenza virus vaccine.

  WARBURTON MF, DUXBURY AE, GREVILLE RW. WARBURTON MF, et al. Med J Aust. 1959 Jun 13;1(24):786-90. doi: 10.5694/j.1326-5377.1959.tb88875.x. Med J Aust. 1959. PMID: 13666175 No abstract available.
• Acute respiratory infections in civilian adults. I. Antibody response to polyvalent influenza--adenovirus inactivated vaccine.

  COX F Jr, TIMM EA, QUINN EL, COLVILLE JM, McLEAN IW. COX F Jr, et al. Henry Ford Hosp Med Bull. 1962 Mar;10:27-33. Henry Ford Hosp Med Bull. 1962. PMID: 13881896 No abstract available.
• The road to a more effective influenza vaccine: Up to date studies and future prospects.

  Sano K, Ainai A, Suzuki T, Hasegawa H. Sano K, et al. Vaccine. 2017 Sep 25;35(40):5388-5395. doi: 10.1016/j.vaccine.2017.08.034. Epub 2017 Aug 31. Vaccine. 2017. PMID: 28866292 Review.
• Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.

  Luke CJ, Subbarao K. Luke CJ, et al. Expert Rev Vaccines. 2014 Jul;13(7):873-83. doi: 10.1586/14760584.2014.922416. Epub 2014 May 23. Expert Rev Vaccines. 2014. PMID: 24855993 Review.